Identification

Name
Magnesium salicylate
Accession Number
DB01397
Type
Small Molecule
Groups
Approved
Description

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.

It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects.

Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.

Structure
Thumb
Synonyms
  • Magnesium salicylate anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Magnesium salicylate tetrahydrate41728CY7UX18917-95-8CWQGWAKCTBFURY-UHFFFAOYSA-J
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arthriten TabletsTablet325 mgOralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Back-ese M Tab 325mgTablet325 mgOralG.T. Fulford Pharmaceuticals1985-12-311998-06-25Canada
Back-ese M Tablets 325 mgTablet325 mgOralDannorth Laboratories Inc.1980-12-312000-07-19Canada
Backache AidTablet, film coated580 mg/1OralL&R Distributors, Inc.1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralRite Aid1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralCVS Health1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet, film coated580 mg/1OralLnk International, Inc.1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet580 mg/1OralWalgreen1998-11-072018-04-10Us
Doan's Backache Pills 325mgTablet325 mgOralNovartis1988-12-311998-07-08Canada
Doans Extra StrengthTablet580 mg/1OralDr Reddy's Laboratories2013-05-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Back ReliefMagnesium salicylate (200 mg/1) + Acetaminophen (200 mg/1)TabletOralNorth Safety Products2013-05-14Not applicableUs
Diurex Water PillsMagnesium salicylate (162.5 mg/1) + Caffeine (50 mg/1)Tablet, coatedOralAlva Amco Pharmacal Companies, Inc.2005-05-15Not applicableUs
MEDIQUE Back Pain OffMagnesium salicylate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1)Tablet, film coatedOralUnifirst First Aid2008-12-30Not applicableUs
Otis Clapp Back QuellMagnesium salicylate (200 mg/1) + Acetaminophen (200 mg/1)Tablet, film coatedOralUnifirst First Aid2008-12-30Not applicableUs
Pain Aid BRFMagnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1)TabletOralZee Medical Inc2012-08-19Not applicableUs
Pamprin Cramp Menstrual Pain ReliefMagnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1) + Pamabrom (25 mg/1)TabletOralChattem, Inc.1983-01-01Not applicableUs
Trilisate TabMagnesium salicylate (362 mg) + Choline salicylate (293 mg)TabletOralPurdue Pharma1979-12-312002-07-30Canada
Vica-cetMagnesium salicylate (250 mg/1) + Acetaminophen (250 mg/1)TabletOralProvision Medical2015-04-03Not applicableUs
Categories
UNII
JQ69D454N1
CAS number
18917-89-0
Weight
Average: 298.531
Monoisotopic: 298.03277995
Chemical Formula
C14H10MgO6
InChI Key
MQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2-hydroxybenzoate)
SMILES
[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Magnesium salicylate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabMagnesium salicylate may increase the anticoagulant activities of Abciximab.Approved
AcebutololMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acemetacin.Approved
AcenocoumarolMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Magnesium salicylate.Approved, Vet Approved
AclarubicinMagnesium salicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Magnesium salicylate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclometasone.Approved
AlcuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium salicylate.Approved
AlfacalcidolThe serum concentration of Magnesium salicylate can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AliskirenMagnesium salicylate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alminoprofen.Experimental
AlprenololMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Amcinonide.Approved
AmikacinMagnesium salicylate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMagnesium salicylate may decrease the antihypertensive activities of Amiloride.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium salicylate.Approved
AmrubicinMagnesium salicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMagnesium salicylate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anisodamine.Investigational
annamycinMagnesium salicylate may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.Approved
Antithrombin III humanMagnesium salicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMagnesium salicylate may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Apocynin.Investigational
ApramycinMagnesium salicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Apremilast.Approved, Investigational
ArbekacinMagnesium salicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMagnesium salicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMagnesium salicylate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Atamestane.Investigational
AtenololMagnesium salicylate may decrease the antihypertensive activities of Atenolol.Approved
AtracuriumMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium salicylate.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium salicylate.Investigational
BalsalazideMagnesium salicylate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium salicylate.Approved
BecaplerminMagnesium salicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMagnesium salicylate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMagnesium salicylate may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Magnesium salicylate.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Magnesium salicylate.Experimental
BendazacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium salicylate.Approved, Investigational
BenorilateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Magnesium salicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betamethasone.Approved, Vet Approved
BetaxololMagnesium salicylate may decrease the antihypertensive activities of Betaxolol.Approved
BevantololMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
BisoprololMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMagnesium salicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bucillamine.Investigational
BucindololMagnesium salicylate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bufexamac.Experimental
BufuralolMagnesium salicylate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bumadizone.Experimental
BumetanideMagnesium salicylate may decrease the diuretic activities of Bumetanide.Approved
BupranololMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.Approved
CalcitriolThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Magnesium salicylate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Magnesium salicylate.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Magnesium salicylate.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium salicylate.Investigational
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Magnesium salicylate.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate.Approved, Vet Approved, Withdrawn
CarteololMagnesium salicylate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMagnesium salicylate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Magnesium salicylate.Approved, Investigational
CeliprololMagnesium salicylate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMagnesium salicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
ChlortetracyclineMagnesium salicylate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium salicylate.Approved, Investigational
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium salicylate.Approved, Investigational
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational, Withdrawn
CisatracuriumMagnesium salicylate may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateMagnesium salicylate may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
Citric AcidMagnesium salicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium salicylate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Magnesium salicylate.Vet Approved
CloranololMagnesium salicylate may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Magnesium salicylate.Experimental
CyclosporineMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with D-Limonene.Investigational
Dabigatran etexilateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMagnesium salicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMagnesium salicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMagnesium salicylate may increase the anticoagulant activities of Darexaban.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium salicylate.Experimental
DaunorubicinMagnesium salicylate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DecamethoniumMagnesium salicylate may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Magnesium salicylate.Experimental
DemeclocyclineMagnesium salicylate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesirudinMagnesium salicylate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Magnesium salicylate.Approved, Investigational
DextranMagnesium salicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Magnesium salicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Magnesium salicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Magnesium salicylate may increase the anticoagulant activities of Dextran 75.Approved
DibekacinMagnesium salicylate may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate.Approved, Vet Approved
DicoumarolMagnesium salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate.Approved
DihydrostreptomycinMagnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium salicylate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Magnesium salicylate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Magnesium salicylate.Approved
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium salicylate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate.Approved
Domoic AcidMagnesium salicylate may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium salicylate.Investigational
Doxacurium chlorideMagnesium salicylate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinMagnesium salicylate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineMagnesium salicylate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneMagnesium salicylate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with E-6201.Investigational
Edetic AcidMagnesium salicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMagnesium salicylate may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium salicylate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium salicylate.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Magnesium salicylate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Magnesium salicylate.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
EnoxaparinMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Magnesium salicylate.Experimental
EpanololMagnesium salicylate may decrease the antihypertensive activities of Epanolol.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium salicylate.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Epirizole.Approved
EpirubicinMagnesium salicylate may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMagnesium salicylate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.Approved
EquileninThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilin.Approved
EsmololMagnesium salicylate may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone sulfate.Approved
Etacrynic acidMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium salicylate.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Magnesium salicylate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fenbufen.Approved
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium salicylate.Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Magnesium salicylate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Feprazone.Experimental
Ferulic acidMagnesium salicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Magnesium salicylate.Approved, Investigational
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium salicylate.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Magnesium salicylate.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone.Approved
FluindioneMagnesium salicylate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Magnesium salicylate.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium salicylate.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Magnesium salicylate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Magnesium salicylate.Approved, Nutraceutical, Vet Approved
FondaparinuxMagnesium salicylate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMagnesium salicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.Approved
FramycetinMagnesium salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMagnesium salicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabapentinMagnesium salicylate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
GabexateMagnesium salicylate may increase the anticoagulant activities of Gabexate.Investigational
GallamineMagnesium salicylate may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMagnesium salicylate may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium salicylate.Investigational
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Magnesium salicylate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Magnesium salicylate.Approved, Withdrawn
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
GeneticinMagnesium salicylate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMagnesium salicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMagnesium salicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Magnesium salicylate may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium salicylate.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HE3286.Investigational
HeparinMagnesium salicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Higenamine.Investigational
HydralazineMagnesium salicylate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
Hygromycin BMagnesium salicylate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icatibant.Approved
IdarubicinMagnesium salicylate may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxMagnesium salicylate may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Magnesium salicylate.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.Approved
IndenololMagnesium salicylate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Indoprofen.Withdrawn
INNO-206Magnesium salicylate may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.Approved, Investigational
IsepamicinMagnesium salicylate may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Isoxicam.Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Istaroxime.Investigational
KanamycinMagnesium salicylate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate.Approved
LabetalolMagnesium salicylate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium salicylate.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium salicylate.Approved, Investigational
LandiololMagnesium salicylate may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Magnesium salicylate.Approved, Investigational
LepirudinMagnesium salicylate may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.Approved, Investigational
LetaxabanMagnesium salicylate may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololMagnesium salicylate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium salicylate.Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Magnesium salicylate.Experimental
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
Lipoic AcidMagnesium salicylate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Magnesium salicylate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.Approved
LonazolacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Magnesium salicylate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Magnesium salicylate.Vet Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium salicylate.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate.Approved
MelagatranMagnesium salicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.Approved, Vet Approved
MepindololMagnesium salicylate may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineMagnesium salicylate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.Approved
MetocurineMagnesium salicylate may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium salicylate may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.Approved
MetoprololMagnesium salicylate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMagnesium salicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium salicylate.Investigational, Withdrawn
MicronomicinMagnesium salicylate may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MinocyclineMagnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Magnesium salicylate.Approved
MivacuriumMagnesium salicylate may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Magnesium salicylate.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Magnesium salicylate.Approved
NadololMagnesium salicylate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMagnesium salicylate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMagnesium salicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium salicylate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium salicylate.Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 1022.Investigational
NeamineMagnesium salicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMagnesium salicylate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Magnesium salicylate.Investigational
NeomycinMagnesium salicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinMagnesium salicylate may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Magnesium salicylate.Approved
NetilmicinMagnesium salicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium salicylate.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium salicylate.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium salicylate.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nitroaspirin.Investigational
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.Approved
OlsalazineMagnesium salicylate may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Magnesium salicylate.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Orgotein.Vet Approved
OtamixabanMagnesium salicylate may increase the anticoagulant activities of Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Magnesium salicylate.Experimental, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Magnesium salicylate.Experimental
OxprenololMagnesium salicylate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium salicylate.Approved
PancuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parecoxib.Approved
ParomomycinMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parthenolide.Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium salicylate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Magnesium salicylate.Approved
PenbutololMagnesium salicylate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMagnesium salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium salicylate.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Magnesium salicylate.Approved
PhenindioneMagnesium salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMagnesium salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.Approved, Investigational
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium salicylate.Approved
PindololMagnesium salicylate may decrease the antihypertensive activities of Pindolol.Approved
PipecuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Magnesium salicylate.Experimental
PirarubicinMagnesium salicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMagnesium salicylate may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Magnesium salicylate.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirprofen.Experimental
Platelet Activating FactorMagnesium salicylate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMagnesium salicylate may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinMagnesium salicylate may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Magnesium salicylate.Approved
PractololMagnesium salicylate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Magnesium salicylate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium salicylate.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pregnenolone.Experimental, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium salicylate.Withdrawn
ProbenecidThe serum concentration of Magnesium salicylate can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Propacetamol.Approved, Investigational
PropranololMagnesium salicylate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Magnesium salicylate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Magnesium salicylate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Magnesium salicylate.Vet Approved
Protein CMagnesium salicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanMagnesium salicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMagnesium salicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium salicylate.Investigational
PTC299The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with PTC299.Investigational
PuromycinMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrantelMagnesium salicylate may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium salicylate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Magnesium salicylate.Approved
RapacuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMagnesium salicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rimexolone.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
RivaroxabanMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RocuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Magnesium salicylate.Investigational, Withdrawn
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Magnesium salicylate.Experimental
SabarubicinMagnesium salicylate may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Magnesium salicylate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium salicylate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Magnesium salicylate.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Serrapeptase.Investigational
SisomicinMagnesium salicylate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Magnesium salicylate.Experimental, Investigational
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium salicylate.Approved
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Magnesium salicylate.Approved
SotalolMagnesium salicylate may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMagnesium salicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
SpectinomycinMagnesium salicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Magnesium salicylate.Approved
SpironolactoneMagnesium salicylate may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with SRT501.Investigational
StreptomycinMagnesium salicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMagnesium salicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SuccinylcholineMagnesium salicylate may increase the neuromuscular blocking activities of Succinylcholine.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Magnesium salicylate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate.Approved
SulodexideMagnesium salicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Magnesium salicylate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Suxibuzone.Experimental
TacrolimusMagnesium salicylate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Magnesium salicylate.Approved
TalinololMagnesium salicylate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Magnesium salicylate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Magnesium salicylate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium salicylate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium salicylate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Magnesium salicylate.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Magnesium salicylate.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Teriflunomide.Approved
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Magnesium salicylate.Experimental
TertatololMagnesium salicylate may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium salicylate.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium salicylate.Approved, Investigational, Vet Approved
TimololMagnesium salicylate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tixocortol.Approved
TobramycinMagnesium salicylate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.Approved
TorasemideMagnesium salicylate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Magnesium salicylate.Approved
TranilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMagnesium salicylate may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triptolide.Investigational
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational, Withdrawn
TroxerutinMagnesium salicylate may increase the anticoagulant activities of Troxerutin.Investigational
TubocurarineMagnesium salicylate may increase the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Magnesium salicylate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Magnesium salicylate.Investigational, Withdrawn
ValrubicinMagnesium salicylate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Magnesium salicylate.Approved
VecuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium salicylate.Investigational
WarfarinMagnesium salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMagnesium salicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zaltoprofen.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium salicylate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Magnesium salicylate.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Magnesium salicylate.Experimental
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium salicylate.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinMagnesium salicylate may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinMagnesium salicylate may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.

US5043168
General References
Not Available
External Links
Human Metabolome Database
HMDB15469
KEGG Compound
C07995
PubChem Compound
54684589
PubChem Substance
46508713
ChemSpider
58278
ChEBI
6640
ChEMBL
CHEMBL2106755
PharmGKB
PA450300
Wikipedia
Magnesium_salicylate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral325 mg
Tablet, film coatedOral580 mg/1
Tablet, coatedOral
TabletOral580 mg/1
CapsuleOral580 mg/1
TabletOral650 mg
Tablet, film coatedOral
TabletOral
Prices
Unit descriptionCostUnit
Tricosal 1000 mg tablet1.23USD tablet
Choline mag trisal 1 gm tablet1.15USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Novasal 600 mg tablet0.75USD tablet
Choline mag trisal 500 mg tablet0.64USD tablet
Doan's ex strength 580 mg tablet0.22USD tablet
CVS Pharmacy backache rlf 580 mg caplet0.18USD caplet
Doan's regular 325 mg tablet0.18USD tablet
Keygesic-10 650 mg tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0686 mg/mLALOGPS
logP2.86ALOGPS
logP1.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5741
Blood Brain Barrier+0.829
Caco-2 permeable+0.5941
P-glycoprotein substrateNon-substrate0.6758
P-glycoprotein inhibitor INon-inhibitor0.9704
P-glycoprotein inhibitor IINon-inhibitor0.9768
Renal organic cation transporterNon-inhibitor0.8975
CYP450 2C9 substrateNon-substrate0.7872
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateNon-substrate0.7282
CYP450 1A2 substrateNon-inhibitor0.8837
CYP450 2C9 inhibitorNon-inhibitor0.5705
CYP450 2D6 inhibitorNon-inhibitor0.9113
CYP450 2C19 inhibitorNon-inhibitor0.8537
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9021
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8587
BiodegradationReady biodegradable0.8277
Rat acute toxicity2.3552 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.9555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts
show 2 more
Substituents
Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid
show 7 more
Molecular Framework
Not Available
External Descriptors
benzenes, carbonyl compound (CHEBI:6640)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441]

Drug created on July 08, 2007 11:04 / Updated on November 09, 2017 02:59